[The French experience with moxalactam in pneumology].
Twenty-nine patients, aged 19 to 87, were treated for an infection of the lower respiratory tract (pneumonia, bronchopneumonia, bronchitis, pulmonary abscess, pleuritis) due to a pathogen with in vitro sensitivity to the antibiotic (pneumococcus, hemophilus, anaerobic organisms . . .). Patients were given Moxalactam as the only antibacterial treatment. In most instances, excellent results (24 successes, i.e. 84% of cases) were recorded with two daily intramuscular injections of 1 g each. Biologic tolerance was satisfactory. Possible clinical side-effects are rashes and local pain during the injection. We conclude that Moxalactam is very effective in severe lower respiratory tract infections, with a daily dosage of 30 mg/kg.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D001996:Bronchopneumonia / Q000188:drug therapy; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005602:France; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009070:Moxalactam; D011014:Pneumonia / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002513:Cephamycins; D009070:Moxalactam
L'expérience française de moxalactam en pneumologie.